News

Archive by author: International AIDS SocietyReturn
RSS
  IAS – the International AIDS Society – applauds plans to nominate Dr John Nkengasong to lead the President’s Emergency Plan for AIDS Relief (PEPFAR). Born in Cameroon, Dr Nkengasong has worked for many years in Africa, the world’s most heavily HIV-affected region where many PEPFAR programmes are implemented. “The role of African leadership is vital in the HIV response,” IAS President Adeeba Kamarulzaman said. “If confirmed in this position, Dr John Nkengasong’s understanding of the s...
Read More
Categories: | Tags: | View Count: (2058)
  Yesterday Johnson and Johnson and its global partners announced that they would discontinue the large-scale Imbokodo HIV Vaccine Trial. Initial results showed that the vaccine did not provide significant protection against HIV infection in young women in sub-Saharan Africa. Despite this disappointing news, IAS – the International AIDS Society – emphasizes the importance of continued investment and engagement in trials to find an effective vaccine. There is still a lot to be learned from thi...
Read More
Categories: | Tags: | View Count: (1314)
“IAS – the International AIDS Society – warmly welcomes the news that a COVID-19 vaccine will soon also be produced in South Africa. Suffering driven by vaccine inequity would largely be a thing of the past if low- to middle-income countries had the capacity to control the production and distribution of life-saving vaccines. “But this good news comes with caveats. To truly empower low- to middle-income countries in the response to COVID-19 and future pandemics, the transfer of technologies ...
Read More
Categories: Statement, News | Tags: | View Count: (1134)
It is my great honour to announce that Dr Birgit Poniatowski is the next Executive Director of IAS – the International AIDS Society. She assumes the role with immediate effect.
Read More
Categories: News | Tags: | View Count: (3353)
New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill (emtricitabine/tenofovir disoproxil fumarate) in a trial of women at increased risk of HIV acquisition.
Read More
Categories: News | Tags: | View Count: (3357)

IAS statement: Ending racism involves us all

posted on
As champions of health and rights, we add our voices to the global chorus condemning the murders of George Floyd, Ahmaud Arbery, Breonna Taylor and countless others – and denounce the structural racism that enabled their deaths.
Read More
Categories: Statement | Tags: | View Count: (3724)

Media Contact

IAS Media Team
[email protected]